By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


NICE changes dronedarone guidance

NICE has changed draft recommendations on the use of dronedarone (Multaq) for atrial fibrillation – a disturbanceof the heart’s rhythm.

The institute has revised its first view that the drug should not be used and is now recommending the drug as a second-line treatment in people with additional cardiovascular risk factors whose AF has not been controlled by first-line therapy, usually including beta-blockers.


Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!